Omnicom Group
OMC
Market cap $14.2B

72.75 USD

-0.68

0.93%

At close Jul 11, 4:00 PM EDT

After hours

73.50

+0.75

1.03%

1 day

-0.93%

5 days

-2.23%

1 month

-0.75%

3 months

-3.77%

6 months

-12.52%

Year to date

-15.84%

1 year

-21.16%

5 years

33.41%

10 years

0.14%

About: Omnicom is a holding company that owns several advertising agencies and related firms. It provides traditional and digital advertising services that include creative design, market research, data analytics, and ad placement. In addition, Omnicom provides outsourced public relations and other communications services. The firm operates globally, providing services in more than 70 countries; it generates more than half of its revenue in North America and nearly 30% in Europe. The firm announced plans to merge with Interpublic Group in December 2024, pending regulatory approval.

Employees: 74,900

Communication Services Advertising Agencies

0

Funds holding %

of 7,312 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

218% more call options, than puts

Call options by funds: $50.7M | Put options by funds: $15.9M

44% more first-time investments, than exits

New positions opened: 128 | Existing positions closed: 89

16% more repeat investments, than reductions

Existing positions increased: 368 | Existing positions reduced: 318

4.46% more ownership

Funds ownership: 98.5% [Q4 2024] → 102.97% (+4.46%) [Q1 2025]

2% more funds holding

Funds holding: 935 [Q4 2024] → 956 (+21) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q4 2024] → 3 (+0) [Q1 2025]

2% less capital invested

Capital invested by funds: $17B [Q4 2024] → $16.8B (-$288M) [Q1 2025]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$80

10%

upside

Avg. target

$89

22%

upside

High target

$103

42%

upside

5 analyst ratings

2 positive

40%

3 neutral

60%

0 negative

0%

JP Morgan David Karnovsky	32%upside $96	Overweight Maintained	10 Jul 2025
Barclays Julien Roch	10%upside $80	Equal-Weight Downgraded	25 Jun 2025
B of A Securities Adrien de Saint Hilaire	10%upside $80	Neutral Upgraded	23 Jun 2025
Wells Fargo Steven Cahall	15%upside $84	Equal-Weight Maintained	16 Apr 2025
Citigroup Jason Bazinet	42%upside $103	Buy Reinstated	15 Apr 2025

See Analyst Rankings

Financial journalist opinion

Based on 22 articles about OMC published over the past 30 days

Zacks Investment Research

Exploring Analyst Estimates for Omnicom (OMC) Q2 Earnings, Beyond Revenue and EPS

Besides Wall Street's top-and-bottom-line estimates for Omnicom (OMC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.

Exploring Analyst Estimates for Omnicom (OMC) Q2 Earnings, Beyond Revenue and EPS

Zacks Investment Research

Bet on 5 Top-Ranked Stocks With Rising P/E

CSW, ASAN, and others show rising P/E trends -- suggesting breakout potential backed by strong earnings surprises.

Bet on 5 Top-Ranked Stocks With Rising P/E

Kristin Hollins Appointed FleishmanHillard California General Manager

Agency Veteran and Strategic Advisor to Global Brands Will Lead Growth and Innovation Across West Coast ST. LOUIS , July 10, 2025 /PRNewswire/ -- FleishmanHillard today announced the appointment of Kristin Hollins as general manager for California.

Kristin Hollins Appointed FleishmanHillard California General Manager

Omnicom Group Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Omnicom Group Inc. OMC will release earnings results for the second quarter, after the closing bell on Tuesday, July 15.

Omnicom Group Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Omnicom Schedules Second Quarter 2025 Earnings Release and Conference Call

NEW YORK , July 9, 2025 /PRNewswire/ -- Omnicom (NYSE: OMC) will publish its second quarter 2025 results on Tuesday, July 15, 2025 after the New York Stock Exchange close of trading. The company will also host a conference call to review such financial results on Tuesday, July 15, 2025, starting at 4:30 p.m.

Omnicom Schedules Second Quarter 2025 Earnings Release and Conference Call

Zacks Investment Research

Why Omnicom (OMC) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Omnicom (OMC) is a Top Value Stock for the Long-Term

Zacks Investment Research

All You Need to Know About Omnicom (OMC) Rating Upgrade to Buy

Omnicom (OMC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Omnicom (OMC) Rating Upgrade to Buy

Zacks Investment Research

Can Omnicom (OMC) Climb 29.41% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 29.4% upside potential for Omnicom (OMC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Can Omnicom (OMC) Climb 29.41% to Reach the Level Wall Street Analysts Expect?

Zacks Investment Research

Should Value Investors Buy Omnicom Group (OMC) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Omnicom Group (OMC) Stock?

Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades

Omnicom cross-agency collaboration to drive technology-led, innovative launch strategy Partnership brings together promising science, top-tier talent, and advanced technologies to enable a faster, smarter, and more effective path to address a critical public health need SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced it has named Omnicom (NYSE: OMC) as its strategic innovation partner and agency of record to lead initiatives in support of Achieve's planning for U.S. commercial launch. “We're excited to expand our partnership with Omnicom, building on the strong foundation we've established over the past several years,” said Jaime Xinos, Chief Commercial Officer of Achieve Life Sciences.

Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades

See News Rankings

Charts implemented using Lightweight Charts™